Qurient Co. Ltd - Asset Resilience Ratio

Latest as of June 2026: 71.23%

Qurient Co. Ltd (115180) has an Asset Resilience Ratio of 71.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 115180 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩32.45 Billion
≈ $21.99 Million USD Cash + Short-term Investments

Total Assets

₩45.56 Billion
≈ $30.88 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Qurient Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Qurient Co. Ltd.

Liquid Assets Composition Over Time

This chart breaks down Qurient Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 115180 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩32.45 Billion 71.23%
Total Liquid Assets ₩32.45 Billion 71.23%

Asset Resilience Insights

  • Very High Liquidity: Qurient Co. Ltd maintains exceptional liquid asset reserves at 71.23% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Qurient Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Qurient Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for Qurient Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Qurient Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 46.80% ₩29.02 Billion
≈ $19.66 Million
₩61.99 Billion
≈ $42.01 Million
-23.82pp
2024-12-31 70.62% ₩46.31 Billion
≈ $31.38 Million
₩65.57 Billion
≈ $44.44 Million
-7.24pp
2023-12-31 77.86% ₩40.88 Billion
≈ $27.70 Million
₩52.50 Billion
≈ $35.58 Million
+9.74pp
2022-12-31 68.12% ₩26.17 Billion
≈ $17.73 Million
₩38.41 Billion
≈ $26.03 Million
+10.09pp
2021-12-31 58.03% ₩33.44 Billion
≈ $22.66 Million
₩57.62 Billion
≈ $39.05 Million
-22.76pp
2018-12-31 80.80% ₩34.90 Billion
≈ $23.65 Million
₩43.20 Billion
≈ $29.27 Million
+17.69pp
2017-12-31 63.10% ₩9.89 Billion
≈ $6.70 Million
₩15.68 Billion
≈ $10.62 Million
+55.48pp
2016-12-31 7.62% ₩2.00 Billion
≈ $1.36 Million
₩26.24 Billion
≈ $17.78 Million
--
pp = percentage points

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$540.41 Million
₩797.43 Billion KRW
Market Cap Rank
#11947 Global
#324 in Korea
Share Price
₩21400.00
Change (1 day)
-4.46%
52-Week Range
₩14320.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more